Recent events
Recent events tied to this brand in public sources.
Back to profile15 entries
2021
NOXXON and MSD collaborate on NOX-A12 study
NOXXON and MSD entered a collaboration for MSD to provide pembrolizumab (Keytruda) and expert advice for the OPTIMUS study of NOX-A12 in second-line pancreatic cancer.
2021
FDA approves Keytruda and Lenvima combination for advanced kidney cancer
The FDA approved MSD's Keytruda and Eisai's Lenvima combination as first-line treatment for adults with advanced renal cell carcinoma.
2021
BioInvent and MSD enter a clinical-trial collaboration for BI-1808 and KEYTRUDA
BioInvent announced a second clinical-trial collaboration and supply agreement with MSD to evaluate BioInvent’s BI-1808 with MSD’s KEYTRUDA in a Phase 1/2a trial involving patients with lung and ovarian cancer.
2021
FDA approves KEYTRUDA for high-risk early-stage triple-negative breast cancer
The U.S. Food and Drug Administration approved Merck's KEYTRUDA, in combination with chemotherapy before surgery and as a single agent after surgery, for patients with high-risk early-stage triple-negative breast cancer.
2021
FDA approves Keytruda–Lenvima combination for advanced endometrial carcinoma
The U.S. Food and Drug Administration approved Keytruda in combination with Lenvima for certain patients with advanced endometrial carcinoma following prior systemic therapy who are not candidates for curative surgery or radiation.
2021
Dracen and Merck enter clinical trial and supply agreement for sirpiglenastat and KEYTRUDA
Dracen announced that it had entered into a clinical trial and supply agreement with Merck to evaluate sirpiglenastat in combination with KEYTRUDA in patients with solid tumors. The announced Phase 1b trial is expected to begin by the first quarter of 2022.
2020
Sanofi and MSD agree to test THOR-707 with Keytruda
Sanofi entered an agreement with MSD to collaborate on a phase II trial evaluating Sanofi's investigational candidate THOR-707 alongside MSD's Keytruda.
2020
QBiotics and MSD clinical collaboration
QBiotics announced that it had entered into an agreement with MSD to evaluate tigilanol tiglate in combination with Keytruda in patients with unresectable melanoma.
2020
FDA approves a new KEYTRUDA indication
The FDA approved KEYTRUDA monotherapy for certain adult and pediatric patients with unresectable or metastatic TMB-H solid tumors after prior treatment when no satisfactory alternative treatment options are available. The indication was approved under accelerated approval.
2020
FDA approves FoundationOne CDx as a KEYTRUDA companion diagnostic
The FDA approved FoundationOne CDx as the companion diagnostic to identify patients with TMB-H solid tumors who may benefit from KEYTRUDA monotherapy.
2020
RefleXion and Merck announce clinical collaboration
RefleXion Medical announced a clinical collaboration with Merck to evaluate the safety and efficacy of KEYTRUDA in combination with biology-guided radiotherapy in randomized controlled clinical trials for multiple late-stage cancers, including non-small cell lung cancer.
2020
FDA approves six-week Keytruda dosing option
The FDA approved a 400 mg every-six-weeks dosing option for Keytruda for adult patients across all cancer types for which the drug is used, including patients taking it alone or with other medications. The option is in addition to the existing 200 mg every-three-weeks dose.
2020
FDA approves Keytruda for certain bladder cancer patients
The FDA approved Keytruda for patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors, who are ineligible for or chose not to undergo cystectomy.
2019
GSK announces planned INDUCE-3 trial
GlaxoSmithKline announced that it would support a planned Phase II/III trial combining GSK3359609 with pembrolizumab for first-line recurrent or metastatic head and neck squamous cell carcinoma. The trial was planned to start by the end of 2019.
2017
Merck settles PD-1 patent litigation with BMS and Ono
Merck agreed to pay Bristol-Myers Squibb and Ono Pharmaceutical $625 million and royalties on Keytruda sales to settle patent infringement litigation concerning PD-1 inhibitors. The agreement provided for dismissal of the patent litigation filed against Merck.